These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12962358)

  • 1. Current and future perspectives for levofloxacin in severe Pseudomonas aeruginosa infections.
    Marchetti F; Viale P
    J Chemother; 2003 Aug; 15(4):315-22. PubMed ID: 12962358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
    Epstein SP; Bottone EJ; Asbell PA
    Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vitro investigation of levofloxacin and ciprofloxacin against clinical isolates of Pseudomonas aeruginosa.
    Segatore B; Perilli M; Larosa M; Setacci D; Celenza G; Amicosante G
    Int J Antimicrob Agents; 2007 Oct; 30(4):374-6. PubMed ID: 17659863
    [No Abstract]   [Full Text] [Related]  

  • 6. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin, a broad spectrum anti-infective: from Streptococcus pneumoniae to Pseudomonas aeruginosa.
    Schito AM; Schito GC
    J Chemother; 2004 Apr; 16 Suppl 2():3-7. PubMed ID: 15255554
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
    Sirvent E; Ruiz M; Rodríguez JC; Royo G
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P; Citron DM; Griffith DC; Lomovskaya O; Dudley MN
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced bacterial uptake and bactericidal properties of ofloxacin loaded on bioadhesive hydrogels against Pseudomonas aeruginosa.
    Romero VL; Manzo RH; Alovero FL
    J Chemother; 2010 Oct; 22(5):328-34. PubMed ID: 21123156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.
    Lister PD; Wolter DJ; Wickman PA; Reisbig MD
    J Antimicrob Chemother; 2006 May; 57(5):999-1003. PubMed ID: 16513915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo synergy of levofloxacin or amikacin both in combination with ceftazidime against clinical isolates of Pseudomonas aeruginosa.
    Piccoli L; Guerrini M; Felici A; Marchetti F
    J Chemother; 2005 Aug; 17(4):355-60. PubMed ID: 16167512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa.
    Garrison MW
    Diagn Microbiol Infect Dis; 2006 Jan; 54(1):51-6. PubMed ID: 16368475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
    Prasad SV; Ballal M; Shivananda PG
    Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: evidence of a synergistic effect using time-kill methodology.
    Kresken M; Körber-Irrgang B; Läuffer J; Decker-Burgard S; Davies T
    Int J Antimicrob Agents; 2011 Jul; 38(1):70-5. PubMed ID: 21514795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.
    Lister PD; Wolter DJ
    Clin Infect Dis; 2005 Feb; 40 Suppl 2():S105-14. PubMed ID: 15712098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of efflux-mediated ciprofloxacin and levofloxacin resistance in recent clinical isolates of Pseudomonas aeruginosa and its reversal by the efflux pump inhibitors 1-(1-naphthylmethyl)-piperazine and phenylalanine-arginine-β-naphthylamide.
    Sonnet P; Izard D; Mullié C
    Int J Antimicrob Agents; 2012 Jan; 39(1):77-80. PubMed ID: 21974858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.
    Louie A; Grasso C; Bahniuk N; Van Scoy B; Brown DL; Kulawy R; Drusano GL
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2646-54. PubMed ID: 20368395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance of Pseudomonas aeruginosa to ciprofloxacin and levofloxacin: 1998-2002].
    De Vecchi E; Drago L; Nicola L; Colombo A; Guerra A; Tocalli L; Medaglia M; Gismondo MR
    Infez Med; 2003 Dec; 11(4):196-200. PubMed ID: 14988667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel in vitro pharmacodynamic model simulating ofloxacin pharmacokinetics in the treatment of Pseudomonas aeruginosa biofilm-associated infections.
    Noreddin AM; Elkhatib WF
    J Infect Public Health; 2009; 2(3):120-8. PubMed ID: 20701871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.